Codexis (CDXS) vs Korro Bio (KRRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Codexis (CDXS) has outperformed Korro Bio (KRRO) over the past year, losing 44.9% versus a loss of 78.5%. Over five years, CDXS leads with a -95.0% price change compared with -97.0% for KRRO. Korro Bio is the larger company by market cap ($155.8 million vs $148.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CDXS | KRRO |
|---|---|---|
| Share price | $1.36 | $10.58 |
| Market cap | $148.93M | $155.80M |
| 1-day change | -3.55% | +0.86% |
| YTD return | -13.50% | +30.96% |
| 1-year return | -44.92% | -78.49% |
| 5-year return | -95.02% | -97.05% |
| EPS (TTM) | $-0.33 | $-9.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.98 | $55.89 |
| 52-week low | $0.96 | $5.20 |
| Distance from 52-week high | -54.36% | -81.07% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +351.47% | +90.93% |
| Average volume | 1.11M | 148.80K |
| Shares outstanding | 109.51M | 14.73M |
| Employees | 146 | 57 |
| Sector | Industrials | Health Care |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CDXS has outperformed KRRO by 33.6 percentage points over the past year.
- The two companies sit in different sectors: Codexis in Industrials and Korro Bio in Health Care.
About Codexis
CDXS stock →Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
Industrials · Major Chemicals · 146 employees
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
CDXS vs KRRO FAQ
Which is bigger, Codexis or Korro Bio?
Korro Bio (KRRO) is larger, with a market capitalization of $155.80M compared with $148.93M for Codexis (CDXS).
Which stock has performed better over the past year, CDXS or KRRO?
CDXS returned -44.92% over the past 12 months, compared with -78.49% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Codexis and Korro Bio in the same industry?
No. Codexis is in the Industrials sector, while Korro Bio is in Health Care.